• About Us
  • Advertise
  • Contact Us
  • DMCA
  • Follow on Google News
Sunday, June 1, 2025
  • Login
National Age
  • Home
  • India
    • National
    • State News
  • World
  • Education
  • Lifestyle
    • Health & Fitness
    • Fashion
    • Travel
    • Food
  • Business
  • Tech
    • App News
    • Gadgets
  • Entertainment
  • Auto
  • Sports
  • Others
    • Agriculture
    • Science
    • Astrology
    • Finance/Money
    • Press Release
No Result
View All Result
  • Home
  • India
    • National
    • State News
  • World
  • Education
  • Lifestyle
    • Health & Fitness
    • Fashion
    • Travel
    • Food
  • Business
  • Tech
    • App News
    • Gadgets
  • Entertainment
  • Auto
  • Sports
  • Others
    • Agriculture
    • Science
    • Astrology
    • Finance/Money
    • Press Release
No Result
View All Result
National Age
No Result
View All Result
Home Business

Regrow Biosciences gets USFDA Nod for Phase II trials of ‘OSSGROW’ for Osteonecrosis in the US

National Age by National Age
June 4, 2022
in Business
0
Regrow Biosciences gets USFDA Nod for Phase II trials of 'OSSGROW' for Osteonecrosis in the US
Share on FacebookShare on Twitter

OSSGROW is India’s first FDA (DCGI) approved product that has treated over 1000 patients across 200 hospitals in the country

Mumbai (Maharashtra): Regrow Biosciences, an Indian-centric global biotech company, is glad to announce a breakthrough achievement of getting a USFDA nod for conducting a phase II trial of its lead product ‘OSSGROW,’ an orphan drug that helps in effectively treating  Osteonecrosis, in the US market. The accomplishment reflects the brand’s commitment to delivering a safe, effective, and durable solution to patients suffering from Osteonecrosis, also known as Avascular Necrosis. Furthermore, Regrow Biosciences moves one step closer to attaining a global market monopoly estimated at $5 Bn through this milestone feat.

Osteonecrosis is a prevalent disease in Asia. However, a rare disease in the United States and Europe. Regrow Biosciences has been granted Orphan Drug Designation (ODD) for OSSGROW ® from the USFDA and EMA. Furthermore, after completing Phase 3 clinical trials in India, OSSGROW® received marketing authorization from the Indian FDA (DCGI) in 2017; the product has successfully treated more than 1000 patients across 200 hospitals.

Read ThisAlso

Say Hello to the Smartest Way to Sound — Ooka Audio Launches TWINS 707 Bluetooth Ceiling Speakers

Say Hello to the Smartest Way to Sound — Ooka Audio Launches TWINS 707 Bluetooth Ceiling Speakers

May 28, 2025
Smart Geek Visas Turns Immigration Dreams into Global Success Stories

Smart Geek Visas Turns Immigration Dreams into Global Success Stories

May 27, 2025

Speaking on the recent success, Mr. Satyen Sanghvi, Chief Scientific Officer and Executive Director at Regrow Biosciences Private Limited, said, “Regrow Biosciences welcomes the positive feedback from USFDA from its Pre-IND (Pre-Investigational New Drug) meeting to develop the world’s first biological bone cell therapy product – OSSGROW®, indicated to treat Osteonecrosis or Avascular Necrosis. The Pre-IND feedback and recommendation for Phase 2 clinical trial in a small patient population are very encouraging for the brand, as the company is now working towards IND filing. This positive feeling is backed by the safety and efficacy data of OSSGROW® across 200 hospitals in India for more than five years.”

Osteonecrosis, mainly seen in the hip joint, is a progressive bone disease that leads to the death of bone tissue due to interrupted blood supply. The initial stages are asymptomatic; however, the disease progresses quite rapidly, affecting the structure and eventually the function of the joint. The advanced stage involves the collapse of the femoral head and arthritis. This necessitates the patients who are barely in their 30s and 40s to undergo hip replacement surgery causing severe loss of productivity and decreased quality of life.

About Regrow Biosciences:

Regrow Biosciences Pvt. Ltd. is an Indian-centric global biotech company (www.regrow.in) with an R&D center and GMP manufacturing facility near Pune, India,  and offices in India, the US, and Singapore. The company is dedicated to researching, developing, and commercializing cell and stem cell-based products to target degenerative and life-threatening diseases. The company has crossed several milestones in its decade-long journey, with many firsts like market authorization and a commercial license for OSSGROW® and CARTIGROW® in 2017. UREGROW® was developed in collaboration with BIRAC, the Department of Biotechnology, the Ministry of Science and Technology, and the Government of India. Today with a strong pool of 340 doctor-partner networks across 46 cities, the Regrow Biosciences has transformed the lives of 1500 patients in India. In addition, the company also provides premium services for Cord Blood Stem Cell banking (Biocell®) across 600 Indian cities and has catered to more than 50,000 young parents.

Tags: Indian-centric global biotech companyOrphan Drug Designation (ODD)OSSGROWOsteonecrosisRegrow BiosciencesRegrow Biosciences Private LimitedSatyen Sanghvi
Share8Tweet5Share1SendShareSend
Previous Post

Creating pluralistic society is an important function of museums, public art

Next Post

Adi Pocha Launches his Debut Novel “Behram’s Boat” Published by Leadstart

National Age

National Age

Related Posts

Say Hello to the Smartest Way to Sound — Ooka Audio Launches TWINS 707 Bluetooth Ceiling Speakers
Business

Say Hello to the Smartest Way to Sound — Ooka Audio Launches TWINS 707 Bluetooth Ceiling Speakers

May 28, 2025
Smart Geek Visas Turns Immigration Dreams into Global Success Stories
Business

Smart Geek Visas Turns Immigration Dreams into Global Success Stories

May 27, 2025
More Than Toys: How Reddy Soft is Becoming India’s Favorite Gifting Brand
Business

More Than Toys: How Reddy Soft is Becoming India’s Favorite Gifting Brand

May 23, 2025
In India’s Smaller Cities, a Measured Investment Shift is Underway
Business

In India’s Smaller Cities, a Measured Investment Shift is Underway

May 22, 2025
Quick Scaleup Technologies: How a Patna-Based Startup is Powering Global Digital Growth
Business

Quick Scaleup Technologies: How a Patna-Based Startup is Powering Global Digital Growth

May 20, 2025
ClinicSpots Digital Services: Empowering Healthcare Brands with Proven Digital Growth
Business

ClinicSpots Digital Services: Empowering Healthcare Brands with Proven Digital Growth

May 20, 2025
Next Post
Adi Pocha Launches his Debut Novel "Behram's Boat" Published by Leadstart

Adi Pocha Launches his Debut Novel "Behram's Boat" Published by Leadstart

Rotary announces: 20th Global Poster Painting Competition - The Joy of Colour

Rotary announces: 20th Global Poster Painting Competition

Influencerquipo's presents Top 4 flourishing Ventures

Influencerquipo's presents Top 4 flourishing Ventures

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Trending
  • Comments
  • Latest
Pro Cricket Championship Trophy (PCCT) announced the schedule of their selection trials and matches today

Pro Cricket Championship Trophy (PCCT) announced the schedule of their selection trials and matches today

May 26, 2022
Now our E-store India has become an international company

Now our E-store India has become an international company

November 1, 2022
Rotary announces: 20th Global Poster Painting Competition

Rotary announces: 20th Global Poster Painting Competition

June 8, 2022
On 27th & 28th December at Surat Marriott, Athwalines India’s premier fashion showcase Hi Life Exhibition is back

On 27th & 28th December at Surat Marriott, Athwalines India’s premier fashion showcase Hi Life Exhibition is back

December 26, 2023

Changa Video sharing app crosses 2 million on play store

0

World’s first DeepUV Air Sanitizer, launched by Indian startup Dokat Inc.

0

Japan’s tech start-ups bitgrit and Atrae rolls out professional ‘matching’ app in India offering jobs in India

0

Surat’s company invents – low-cost,high-end ventilator in support of the Aatmanirbhar Bharat Abhiyan

0
TCL Q6 Series: The Real Deal for Tech-Savvy TV Buyers This Year? (Yeah, We’re Looking Closely!)

TCL Q6 Series: The Real Deal for Tech-Savvy TV Buyers This Year? (Yeah, We’re Looking Closely!)

May 30, 2025
Hemant Suresh Avhad – Winner of the 21st Century Emily Dickinson Award

Hemant Suresh Avhad – Winner of the 21st Century Emily Dickinson Award

May 30, 2025
Chander Parkash Malhotra – Winner of the 21st Century Emily Dickinson Award

Chander Parkash Malhotra – Winner of the 21st Century Emily Dickinson Award

May 29, 2025
Rajarshi Choudhury – Winner of the 21st Century Emily Dickinson Award

Rajarshi Choudhury – Winner of the 21st Century Emily Dickinson Award

May 28, 2025

Recent News

TCL Q6 Series: The Real Deal for Tech-Savvy TV Buyers This Year? (Yeah, We’re Looking Closely!)

TCL Q6 Series: The Real Deal for Tech-Savvy TV Buyers This Year? (Yeah, We’re Looking Closely!)

May 30, 2025
Hemant Suresh Avhad – Winner of the 21st Century Emily Dickinson Award

Hemant Suresh Avhad – Winner of the 21st Century Emily Dickinson Award

May 30, 2025
Chander Parkash Malhotra – Winner of the 21st Century Emily Dickinson Award

Chander Parkash Malhotra – Winner of the 21st Century Emily Dickinson Award

May 29, 2025
Rajarshi Choudhury – Winner of the 21st Century Emily Dickinson Award

Rajarshi Choudhury – Winner of the 21st Century Emily Dickinson Award

May 28, 2025

www.nationalage.com, digital news and story platform bring you the news, articles, stories, and opinions on the latest happenings worldwide covering various sectors like nation, politics, and governance, social sector, review, foreign affairs, defence and security, latest review, lifestyle, entertainment, sports, technology, auto sectors, education, business and start-ups updates, Agriculture, Science, finance, money, food, and culture, etc.

If you have any query regarding Site, Advertisement, and any other issue, please feel free to contact at [email protected]

Follow Us

Browse by Category

  • Agriculture
  • App News
  • Astrology
  • Auto
  • Business
  • Education
  • Entertainment
  • Fashion
  • Finance/Money
  • Food
  • Gadgets
  • Health & Fitness
  • Lifestyle
  • National
  • Photography
  • Politics
  • Press Release
  • Religion
  • Science
  • Social Work
  • Sports
  • State News
  • Tech
  • Travel
  • Uncategorized
  • World
TCL Q6 Series: The Real Deal for Tech-Savvy TV Buyers This Year? (Yeah, We’re Looking Closely!)

TCL Q6 Series: The Real Deal for Tech-Savvy TV Buyers This Year? (Yeah, We’re Looking Closely!)

May 30, 2025
Hemant Suresh Avhad – Winner of the 21st Century Emily Dickinson Award

Hemant Suresh Avhad – Winner of the 21st Century Emily Dickinson Award

May 30, 2025
Chander Parkash Malhotra – Winner of the 21st Century Emily Dickinson Award

Chander Parkash Malhotra – Winner of the 21st Century Emily Dickinson Award

May 29, 2025
  • About Us
  • Advertise
  • Contact Us
  • DMCA
  • Follow on Google News

Copyright © 2021 National Age

No Result
View All Result
  • About Us
  • Advertise
  • Contact Us
  • DMCA
  • Home
  • Privacy Policy

Copyright © 2021 National Age

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In